Novartis Reports Results of BYL719 (alpelisib) + fulvestrant in P-III SOLAR-1 trial for HR+/HER2- Advanced Breast Cancer

 Novartis Reports Results of BYL719 (alpelisib) + fulvestrant in P-III SOLAR-1 trial for HR+/HER2- Advanced Breast Cancer

Novartis Reports Results of BYL719 (alpelisib) + fulvestrant in P-III SOLAR-1 trial for HR+/HER2- Advanced Breast Cancer

 Shots:

  • The P-III SOLAR-1 trial assessed BYL719 (300 mg, qd) + fulvestrant (500 mg) vs PBO (fulvestrant) in 572 postmenopausal women in ratio (1:1) with PIK3CA-mutated HR+/HER2- advanced or metastatic breast cancer
  • P-III SOLAR-1 trial results: mPFS (11.0 vs 6.8 mos.), additional 1L therapy mPFS (10.9 vs 3.7 mos.), PIK3CA mutation (3% vs 2%), safe and well- tolerated
  • BYL719 (alpelisib) is an alpha-specific PI3K inhibitor, for suppressing PIK3CA mutations targeted for HR+/HER2- Advanced Breast Cancer

Click here to read full press release/ article | Ref: Novartis | Image: Fortune

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post